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Abstract
Background: Guidelines and evidence-based drug treatment recommendations are usually based on the results of
clinical trials, which have limited generalisability in routine clinical settings due to their restrictive eligibility criteria.
These trials are also conducted in ideal and rigorously controlled settings. N of 1 trials, which are single patient
multiple crossover studies, offer a means of increasing the evidence base and individualising care for individuals in
clinical practice. This systematic review of the N of 1 drug treatment trial aims to investigate its usefulness for
achieving optimal individualised patient care.
Methods: The following databases will be searched for relevant articles: MEDLINE, EMBASE, PsycINFO (all via Ovid),
AMED, CINAHAL (via EBSCO), The Cochrane Library (including CENTRAL, NHS EED, and DARE), and Web of Science
(Thomson Reuters). Supplementary searches will include ongoing trial databases and organisational websites. All N
of 1 trials in which patients have been treated with a drug will be considered. Outcomes will include information
on the clinical usefulness of N of 1 trials—i.e. achievement of optimal individualised care, health-care utilisation of
patients, frequently used practices, experiences of clinical care or participation in N of 1 trials, adherence to
treatment plan, and unwanted effects of the treatment. Screening of included papers will be undertaken
independently by two reviewers, while data extraction and the quality of reporting will be conducted by one
reviewer and checked by another. Both quantitative and qualitative summaries will be reported using appropriate
methods.
Discussion: This review will provide new insights into the clinical utility of N of 1 drug trials in helping participants
find the most acceptable treatment as defined by patients and clinicians based on the selected outcome measures
and the perspectives of participants involved in such trials. Findings from this review will inform the development
of a stakeholder workshop and guidance to help physicians find the optimum therapy for their patients and will
help guide future research on N of 1 trials.
Systematic review registration: PROSPERO CRD42016032452
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Background
Randomised controlled trials (RCTs) are considered to
be the gold standard research method, but they have
some limitations. One issue with RCTs relates to the ap-
plicability of the results to the individual patient. RCTs
might exclude the elderly, children, ethnic groups, and
participants with multiple conditions or rare diseases,
thereby not only limiting the external validity of their re-
sults but also resulting in a paucity of evidence-based in-
formation for these groups. For example, in a review to
assess the representativeness of RCT samples, it was
concluded that they were not always seen as representa-
tive of the patients treated in routine clinical practice
[1]. Furthermore, patients may react differently even
when given the same drug for the same disease, a
phenomenon termed heterogeneity of treatment effect
(HTE). These differences between individuals may mean
that the findings from RCTs are limited. RCTs only pro-
vide an estimate of the average treatment effect and are
usually conducted in ideal settings. Therefore, they are
not necessarily effective for all individual patients in
real-world clinical practice.
These limitations could mean that clinicians are uncer-
tain as to the effectiveness of a drug and might utilise a
trial and error approach to guide treatment choice,
sometimes called the trial of therapy [2]. A trial of ther-
apy involves the provision of a single treatment to a pa-
tient, with the effectiveness of that treatment judged by
the resultant clinical course. Apart from being unstan-
dardised with no study protocols, trials of therapy are
also susceptible to various problems, including the sta-
bility of the condition (current symptoms may subside
with or without treatment), placebo effect, the desire of
patients and doctors to please each other, their expecta-
tions about the treatment effect, regression to the mean
since treatment effect is assessed once, and that only
one treatment may be tested [3]. In the latter case, if the
treatment is found effective the trial is ended with no
further trials carried out on other treatments to deter-
mine if they are equally or even more effective than the
first [2]. All of these factors could lead to false confi-
dence in the primary therapeutic decision, as they all
have an influence on the treatment outcome. Therefore,
there is a need for a more methodologically rigorous ap-
proach to determining the treatment effect in the indi-
vidual patient, for example, the N of trial.
In clinical medicine, the term N of 1 trial has been
used to describe trials with multiple crossover and a re-
peat challenge-withdrawal design; for example, the
ABAB design sequence in which a single patient receives
an intervention during some periods (A) and then re-
ceives the control or alternate intervention or no inter-
vention during the other periods (B) [4, 5]. In N of 1
trials in clinical medicine, individuals are studied during
at least four periods—that is both the A and B phase are
repeated at least once. Patients are switched sequentially
from active drug to control (standard care and placebo)
or between two or more active treatments, or between
specific doses of a drug.
N of 1 trials could help to overcome some of the limi-
tations of the other designs mentioned previously. The
N of 1 trial is a study design that potentially lends itself
more naturally than the RCT to individualising treat-
ment [3], as individualised treatment effect estimates are
generated rather than average treatment effect estimates.
Furthermore, Willke and colleagues have suggested the
use of N of 1 trials as a way of overcoming HTE, as the
data obtained from these trials provide results that are
applicable to the specific participating patients. In con-
trast to the unstandardised trials of therapy, N of 1 trials
offer a more standardised approach for investigating the
effectiveness of a drug. Furthermore, the use of multiple
crossovers, blinding, and randomisation in this design
ensures that results are less susceptible to regression to
the mean, placebo effect, and other forms of bias that
characterise trials of therapy. N of 1 trials could serve as
a means of increasing the evidence base for people with
similar characteristics to those who are typically ex-
cluded from clinical trials. A further advantage of the N
of 1 design is that patients are usually involved in the se-
lection of treatment for investigation, documentation of
processes, and outcomes before the trial, as well as the
selection of final treatment to be administered at the
end of the trial. This promotes patient-centred care and
patient engagement [4, 6]. Due to their higher applicabil-
ity and validity for individual patients when compared to
RCTs, N of 1 trials are judged to be of the highest
strength in terms of clinical decision-making [7]. The
Oxford Centre for Evidence-Based Medicine has also
ranked N of 1 trials as “level 1” evidence for making
treatment decisions in individual patients [8].
There are a number of situations where this design
can be used effectively. Clinicians can use N of 1 trials
for patients with chronic stable conditions who will be
placed on long-term therapy and for whom the effective-
ness of their current treatment is in doubt [2]. The trial
design has been used widely in stable conditions affect-
ing the nervous, respiratory, digestive or musculoskeletal
systems, and in mental and behavioural disorders [9].
When applied to these conditions, it has been suggested
that the drug under consideration should ideally have a
rapid onset of action as shorter treatment periods make
trial processes easier on the patient, although it may be
possible to use drugs with a longer onset of action [2].
Guyatt and colleagues [2] also recommend that the drug
should have a short duration of action to avoid unneces-
sarily long washout periods which could compromise
the feasibility of the trial [2]. The duration of each
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period should take into account the time it takes for a
drug to reach its full effect and the time required for this
effect to subside completely. N of 1 trials are not for
acute, or rapidly progressing diseases, but they have
been used in conditions with episodic symptoms like sei-
zures or migraines [2]. In these cases, the duration of
each treatment period should be long enough for an at-
tack or exacerbation to occur.
Previous reviews of N of 1 trials
There have been two previous systematic reviews of N
of 1 trials [10, 11], neither of which assessed the condi-
tions for which N of 1 trials have been most useful or
the different practices employed by investigators when
conducting these trials. Punja et al. [9, 12] have pub-
lished the results of the systematic review thesis by
Punja [11]. Gabler and colleagues [10] provided an over-
view of N of 1 trials and aimed to determine the extent
to which treatment decisions are influenced by N of 1
trial results and whether N of 1 trials provided sufficient
data to conduct analyses that use a Bayesian framework
for the purpose of estimating HTE or to obtain a more
accurate estimate of treatment effect. They also explored
whether treatment decisions are influenced by participa-
tion in an N of 1 trial, but did not investigate whether
these varied with the condition of a patient. Punja [11]
provided an overview of the methodology and reporting
of N of 1 trials and sought to describe the statistical
methods used to analyse data from N of 1 trials and how
the results from several N of 1 trials could be combined.
The author assessed how outcome measures from N of
1 trials conducted in participants with a similar condi-
tion assessing the same treatment can be aggregated to
obtain average estimates of effect. They also assessed
how these results can be combined across participants
and studies, including RCTs, to obtain estimates of
population-averaged treatment effect. Although studies
comparing N of 1 trials to standard practice have been
undertaken [13, 14], no review exploring the reported
benefit of N of 1 trials in comparison to standard prac-
tice has been conducted. The previous reviews did not
provide information on participants’ perspectives regard-
ing their participation in N of 1 trials. The aim of this
review is to determine the clinical conditions in which N
of 1 trials have been shown to be effective in helping pa-
tients achieve an individualised treatment strategy. Fur-
thermore, this review is looking to see if trials with
patient-selected outcomes are more clinically useful than
trials where patients do not select their outcomes and
also, what influences patients’ choice of outcomes.
Neither of the above reviews examined these aspects.
N of 1 trials often provide estimates of treatment effect
for each drug treatment. This review is not concerned
with the effectiveness of the therapies under investigation
but rather it aims to ascertain whether the process of par-
ticipation in an N of 1 trial is useful in helping the specific
patient or clinician to identify an individualised drug treat-
ment plan. This review will also examine typical practices
in N of 1 trials and whether there is any change in a pa-
tient’s knowledge, attitude or treatment satisfaction after
the trial. Findings from this systematic review will inform
the development of a stakeholder workshop of clinicians
and patients and a guidance which will assist clinicians to
conduct N of 1 trials.
Aims
The aims of the systematic review are to:
1. Provide a detailed typology of the N of 1 trial design.
2. Determine the particular challenges that N of 1
trials can address.
3. Identify the clinical conditions in which they are
useful.
4. Investigate if the N of 1 trial is a clinically useful way
of determining appropriate treatment for an
individual patient.
5. Identify practices in N of 1 trials that could
encourage patient participation.
6. Describe the experiences, views, and perceptions of
participants in N of 1 trials and the factors guiding
patients’ choice of outcomes.
Clinical usefulness will be determined by exploring the
added benefit of N of 1 trials over standard practice and
by analysing individual N of 1 trials. Measures of clinical
utility will include, but not be limited to, the following:
achievement of individualised care or trial objectives,
identification of treatment responders and non-
responders, and improvement in patients’ health care
utilisation such as knowledge about their condition and
self-management habits. As the review is also concerned
with patient participation, the review will seek to identify
practices that might encourage shared decision-making
(e.g. patient selected outcomes, use of subjective out-
come measures like patient diaries, and seeking the pref-
erences of patients) or tailoring of drug treatment to a
specific individual by using pre-trial dose finding. These
examples were identified by reading through the key N
of 1 papers [3, 15, 16].
Research questions
1. What are the different design sequences of N of 1
trials?
2. What are the challenges that N of 1 trials can
address?
3. In which clinical conditions are N of 1 trials more
useful?
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4. Are N of 1 trials more clinically useful compared to
standard practice based on the above measures of
clinical utility?
5. i. Are trials that encourage patient participation
more clinically useful than trials that do not?
ii. Do trials that encourage patient participation have
a lower dropout rate?
6. What are the experiences, views, and perceptions of
participants involved in an N of 1 trial and the
factors guiding patients’ selection of outcomes?
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analysis Protocol (PRISMA-P) statement
guides the reporting of this protocol and is included as
Additional file 1 [17]. The PROSPERO International
Prospective Register of Systematic Reviews, registration
number is CRD42016032452.
Eligibility criteria
Study design
Multiple crossover studies with a repeat challenge-
withdrawal design (treatments are switched sequentially
such as A-B-A-B or A-B-C-A-B-C) will be included. Tri-
als with the sequence A-A-B-B or A-A-B-B-C-C will
only be included if there is an assessed washout period
in between periods that administer the same treatment.
The order of allocation need not be randomised, but at
least one of the treatments under investigation will be a
drug, and studies should aim to determine the effect of a
treatment for individual study participants. In the con-
text of this review, a drug will be defined as any chem-
ical substance or combination of this substance which
may be used, for administration to a person, for the pur-
pose of altering, correcting, or restoring physiological
functions by exercising a metabolic, immunological, or
pharmacological action [18].
Participants
All studies in human participants using the N of 1 trial
design as defined above will be included in the review.
Comparator
Included trials should at least have one of the following
comparators tested for within patients: placebo, or
standard care, or alternative treatment or specific dose(s)
of the same treatment. The washout period will be con-
sidered as a control period if an assessment is
undertaken.
Outcomes
The outcomes referred to below relate to the results of
our study objectives, that is, the properties of the indi-
vidual trials. The outcomes were chosen based on the
Cochrane Consumers and Communication Review
Group’s taxonomy [19], outcomes of relevance to end-
users with regards to effective medicine use [20], reviews
on enhancement of medication adherence [21], and indi-
vidualised care planning [22].
Outcomes will include:
1. In terms of aim 1, the identification of different
study types and their categorisation.
2. For aim 2, the identification of the clinical
challenges addressed and their categorisation.
3. The identification of the clinical conditions for
which N of 1 trials have been conducted and their
categorisation.
4. Measures of clinical usefulness for aim (4) will
include the following: trial enabled participants to
find the most acceptable treatment or allowed trial
objectives to be met based on the patient, clinician
or researcher’s judgement. Other measures of
usefulness will include identification of treatment
responders and non-responders, improvement in pa-
tients’ health care utilisation, knowledge and under-
standing about their condition, treatment
satisfaction, post-trial preference, self-management
practices, self-efficacy, and ability to access support
and/or information, confidence, and competence.
5. For aim (5), typical practices in N of 1 trials that
could allow patients to participate actively in the
research process and decision-making—that is ele-
ments of shared decision-making or pre-trial dose
finding. These may include patients selecting their
outcomes, use of subjective health and wellbeing
measures, and use of objective health and wellbeing
measures. Data on dropout rates will also be
included.
6. For aim (6), outcomes will include participants’
experiences, views, and perceptions about N of 1
trials.
Exclusion criteria
We will exclude studies without a multiple crossover de-
sign or without a repeat challenge-withdrawal design
(such as A-B, or A-B-C or A-B-A, or A-B-A-C-A-D)
and trials with a crossover design involving simultaneous
treatment on both sides of the body. Molecular/genetic
studies, study protocols, methodological papers, reviews,
and studies which aim to prevent or determine causation
of a disease or in which a drug was not among the treat-
ments will also be excluded.
Search strategy
The following biomedical electronic databases will be
searched for relevant articles: MEDLINE, EMBASE, Psy-
cINFO (all via Ovid), AMED, CINAHAL (via EBSCO),
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The Cochrane Library (including CENTRAL, NHS EED,
and DARE), and Web of Science (Thomson Reuters). A
draft search strategy developed in MEDLINE has identi-
fied approximately 2000 abstracts (see Additional file 2).
This will be adapted for use in the other databases and
grey literature resources. The search strategy, developed
with the help of an information specialist (SB) includes
terms for N of 1 combined using AND with terms for
randomised controlled trial and individualised care, with
no limitation in dates.
The authors are aware that some N of 1 studies are
present in the grey literature; therefore, the following
sources will be searched: Controlled Clinical Trials,
ClinicalTrials.gov, International Clinical Trials Registry
Platform (ICTRP), and Epitemonikos (a systematic re-
view database). Organisational websites will also be
searched: World Health Organization, UK Department of
Health, U.S. Department of Health and Human Services,
American College of Clinical Pharmacology, American
Society for Clinical Pharmacology and Therapeutics,
British Pharmacological Society, Australian Department of
Health and Ageing and Health Canada. Additional papers
will be identified by citation tracking, reference list check-
ing and contacting authors of relevant articles. All searches
will be conducted by one reviewer (WD).
Study selection process
Results of all searches will be exported into Endnote X7
where duplicates identified automatically will be moved
to a separate folder and reported in the final flow dia-
gram. WD will also hand search for additional duplicates
not previously identified by the software. Inter-rater
agreement will be tested prior to the commencement of
the screening process. All titles and abstracts identified
from the search will be screened independently by two
reviewers based on the eligibility criteria. All full text ar-
ticles of potentially relevant papers will be retrieved and
screened independently by two reviewers based on the
same criteria. Discrepancies during the screening
process will be resolved through discussion and where
consensus cannot be achieved, a third reviewer will be
consulted.
Quality assessment
Assessment of study quality of all included papers will
be undertaken by WD and checked for accuracy by an-
other reviewer. Currently, there are no quality assess-
ment tools for the appraisal of N of 1 trials in clinical
medicine. A modified version of the CONSORT exten-
sion for reporting N of 1 Trials (CENT) [5] will be used
to appraise the quantitative papers. This will be in a yes/
no format to determine if the studies reported items in
the checklist. Consolidated criteria for reporting qualita-
tive research (COREQ) [23] and CENT will be modified
and incorporated for the assessment of qualitative pa-
pers. Any discrepancies will be discussed and a third re-
viewer involved when necessary.
Data extraction
A data extraction form will be developed using a modi-
fied version of the Consumers and Communication Re-
view Group’s Data Extraction Template [19]. Data will
be extracted independently by WD and checked for ac-
curacy by another reviewer. The completed forms will
be compared and disagreements discussed with refer-
ence to the original paper. A third reviewer will be con-
sulted if a consensus cannot be reached. Authors of
included N of 1 studies will be contacted and asked to
provide missing data or clarify any ambiguities. If au-
thors are unable to provide relevant information on any
areas of uncertainty (due to missing data or missing de-
tails) in the trial reports, this will be noted.
Data will be extracted on the following: Study
methods- aims and purpose of the study, N of 1 study
design subtype, funding source, competing interests, and
trial coordinator; participant information- country,
setting, number of participants, characteristics of partici-
pants, and nature of the condition; intervention details-
type of intervention, selection of intervention, procedure,
intervention provider, frequency of intervention, compara-
tor, presence or absence of washout, and fidelity; out-
comes- all outcomes regarding clinical usefulness and
typical practices as stated above, selection of outcome (by
whom), method of assessment, timing of measurement,
and dropout rates; themes- relating to participant views,
satisfaction, perception, and attitude towards N of 1 trials
will be extracted; patients’ preferences, experiences of be-
ing in an N of 1 trial, professional opinion about its rele-
vance, factors guiding patient’s choice of an outcome,
other qualitative data identified in the studies and relevant
to the review question will also be extracted.
Data analysis
Depending on the nature of the data extracted, quantita-
tive data will be analysed descriptively. The first, second,
and third aims of the review, i.e. typology of N of 1 trials
based on the design sequences, particular challenges that
they address and conditions in which they have been use-
ful will be identified from the studies. They will be
grouped and presented descriptively using numbers and
percentages for categorical variables and means and stand-
ard deviations or medians and interquartile ranges for
continuous data. It might further be presented in a graph-
ical form to enable mapping of the typology to conditions
in which they have been useful. The fourth aim, which is
the clinical usefulness of N of 1 trials as stated above, will
also be identified and reported. The fifth aim, typical prac-
tices in N of 1 trials as judged by the inclusion of elements
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of shared decision-making or pre-trial dose finding will be
summarised descriptively. Trials with the stated practices
will be compared to trials without them to ascertain if
there are any differences in the clinical usefulness and re-
sults will be presented using percentages.
For the qualitative data, about participants’ experiences
of N of 1 trials, the primary method of synthesis might be
meta-ethnography if appropriate [24]. Meta-ethnography
will be judged as appropriate if there are sufficient papers
containing conceptually rich and detailed qualitative data
to enable translation of studies into one another [25]. A
summary of each paper will be constructed and diagram-
ming or mapping may also help to organise and interpret
data in the initial phases. This involves presenting infor-
mation in a graphical form in order to show the relation-
ship between the data [26]. The key themes and concepts
identified in these studies will form the basis for the syn-
thesis. Variability in accounts due to any of the following
elements will be investigated: study design, participant’s
condition, and methodology. Our analysis will be led by
the study findings themselves, but we also anticipate that
analysis will be informed by the findings in the quantita-
tive synthesis to assess similarities, links, and differences
between the two bodies of literature.
If it is not possible to summarise the data in the man-
ner stated above, a narrative approach will potentially be
used to summarise the quantitative and qualitative data
into a coherent whole [27].
Discussion
The N of 1 trial design offers a means of accurately de-
termining the right medications for end users by tailor-
ing treatment to individual needs, thus ensuring
judicious use of scarce resources. This systematic review
will examine the usefulness of the N of 1 trial as an
intervention for individualising drug treatments in pa-
tients. We are interested in exploring how drugs can be
adapted to suit the individual patient, both socially and
medically. Although there have been two previous re-
views about other aspects of N of 1 trials, to our know-
ledge, no other review has addressed this objective.
Poor quality of some of the studies may bias our re-
sults, and it is also possible that some N of 1 studies will
be missed due to poor reporting and lack of uniformity
in the terms used to describe such trials. We hope to
identify as many relevant papers as possible by contact-
ing authors for literature on N of 1 trials. We have
already developed a comprehensive search strategy and
tested it against the studies included in the Gabler re-
view. Multiple reviewers will be involved at every stage
of the review, which will help to strengthen the quality
of the review. The findings from this review will inform
the development of a stakeholder workshop and guid-
ance to assist clinicians in conducting N of 1 trials.
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Additional file 1: Preferred Reporting Items for Systematic Reviews and
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